Welcome to the Celgene REMS Program

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (thalidomide) and POMALYST® (pomalidomide). The THALOMID REMS® program, REVLI-MID REMS® program, and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:

**Revlimid REMS®**
Visit [www.REVLI-MIDREMS.com](http://www.REVLI-MIDREMS.com), to learn more about the REVLI-MID REMS® program.

**Pomalyst REMS®**
Visit [www.POMALYSTREMS.com](http://www.POMALYSTREMS.com), to learn more about the POMALYST REMS® program.

**THALOMID REMS®**
Visit [www.THALOMIDREMS.com](http://www.THALOMIDREMS.com), to learn more about the THALOMID REMS® program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:

User Name:

Password:

Forgot Password?  Login

Create User Account  Patient Surveys  Encuesta del paciente

Contact Us | Terms of Use | Privacy Policy
© 2003-2017, Celgene Corporation

Reference ID: 4117081
Home Page (after prescriber logon)

Click on a button below to access the corresponding REMS menu of operations for that product: enroll a patient, access an existing or save a new Patient-Physician Agreement Form, complete a prescriber survey or write a prescription.

For **REVlimid REMS®**

*RevlimidREMS®*

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.REVlimidREMS.com, to learn more about the REVlimidREMS® program.

For **PomalySt REMS®**

*PomalyStREMS®*

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.PomalyStREMS.com, to learn more about the PomalyStREMS® program.

For **Thalomid REMS®**

*ThalomidREMS®*

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit www.ThalomidREMS.com, to learn more about the ThalomidREMS® program.

The Prescriber Dashboard is an optional resource that displays the status of patients under your care for a specific Celgene REMS program. A patient search function is also included to access detailed patient history information.

Select the "Manage My Account" button to view your Celgene REMS online account information.

Contact Us | Terms of Use | Privacy Policy
© 2005-2017, Celgene Corporation

Reference ID: 4117081
THALOMID REMS module
Welcome to the THALOMID REMS® program

THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).

THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neutropia.

THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Important information about THALOMID and the THALOMID Risk Evaluation and Mitigation Strategy (REMS) program

- THALOMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential must be treated with THALOMID provided adequate precautions are taken to avoid pregnancy.
- To avoid embryo-fetal exposure, THALOMID is only available under a restricted distribution program called "THALOMID REMS®”.
- Only prescribers and pharmacies certified by the THALOMID REMS® program can prescribe and dispense THALOMID to patients who are enrolled and meet all the conditions of the THALOMID REMS® program.

The goals of the THALOMID risk evaluation and mitigation strategy are as follows:
1. To prevent the risk of embryo-fetal exposure to THALOMID
2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for THALOMID

Download the Celgene REMS mobile app to your iPad by clicking here:
About the THALOMID REMS® program

THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).

THALOMID® is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythematous discoid lupus (DLE).

THALOMID® is not indicated as monotherapy for the treatment of ENL in the presence of moderate to severe manifestations.

THALOMID® is not indicated as monotherapy for the treatment of ENL in the presence of moderate to severe manifestations.

To avoid embryo-fetal exposure, THALOMID® is only available under a restricted distribution program called "THALOMID Risk Evaluation and Mitigation Strategy (REMS)." Only certified prescribers can prescribe THALOMID® and only certified pharmacies can dispense THALOMID® in the THALOMID REMS® program.

In order to receive THALOMID®, all patients must be enrolled in the THALOMID REMS® program and agree to comply with the requirements of the THALOMID REMS® program.

Key points of the THALOMID REMS® program

Prescriber:
- The prescriber enrolls and becomes certified with Celgene for the THALOMID REMS® program.
- The prescriber must complete a Patient Medication Guide and a THALOMID REMS® Patient Education Pamphlet.
- The prescriber must provide information to the patient about the risks of THALOMID® and the importance of follow-up visits.
- The prescriber must obtain a written, signed consent from the patient prior to starting treatment with THALOMID®.
- The prescriber must be aware of the risks of pregnancy in women of childbearing potential and the importance of using effective contraception.
- The prescriber must be aware of the risks of THALOMID® in patients with human immunodeficiency virus (HIV) infection.
- The prescriber must be aware of the risks of THALOMID® in patients with severe renal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hepatic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe cardiac impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe pulmonary impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe neurological impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe endocrine impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hematologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe oncologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe dermatologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe musculoskeletal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe gastrointestinal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe renal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hepatic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe cardiac impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe pulmonary impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe neurological impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe endocrine impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hematologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe oncologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe dermatologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe musculoskeletal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe gastrointestinal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe renal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hepatic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe cardiac impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe pulmonary impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe neurological impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe endocrine impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hematologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe oncologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe dermatologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe musculoskeletal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe gastrointestinal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe renal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hepatic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe cardiac impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe pulmonary impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe neurological impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe endocrine impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hematologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe oncologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe dermatologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe musculoskeletal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe gastrointestinal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe renal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hepatic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe cardiac impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe pulmonary impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe neurological impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe endocrine impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hematologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe oncologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe dermatologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe musculoskeletal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe gastrointestinal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe renal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hepatic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe cardiac impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe pulmonary impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe neurological impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe endocrine impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe hematologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe oncologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe dermatologic impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe musculoskeletal impairment.
- The prescriber must be aware of the risks of THALOMID® in patients with severe gastrointestinal impairment.